MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/02770903.2021.1897835

Медицинская библиотека · The Journal of asthma : official journal of the Association for the Care of Asthma · 2021

Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study.

Enríquez-Rodríguez Ana Isabel, Hermida Valverde Tamara, Romero Álvarez Pedro, López-González Francisco Julián, Gullón Blanco Jose Antonio, Expósito Villegas Ana Rosa, Escobar Fernández María José, Beristáin Urquiza Ana María, Alonso Fernández Miguel Ángel, Gutiérrez Rodríguez Margarita, Castaño De Las Pozas Gema, Jiménez Pérez Jennifer, Fernández Mellado Roberto, García Clemente Marta María, Casan Clara Pere

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVE

Add-on therapy with monoclonal antibodies is the recommended therapy for severe asthmatic patients refractory to maintenance treatment. In randomized control trials, mepolizumab reduced the number of exacerbations, the need of oral corticosteroids (OCS), increased asthma control, and lung function in a population of uncontrolled severe eosinophilic asthmatic patients. In this piece of work, we aimed to assess mepolizumab efficacy and safety in a cohort of patients with severe eosinophilic asthma in real-life conditions.

METHODS

A retrospective study was carried out at eight hospitals from Asturias (Spain). The sample included patients treated with mepolizumab from 1 January 2016 to 31 March 2019. Demographic and clinical variables were collected, including OCS use, asthma control, lung function, and exacerbation rate.

RESULTS

Sixty-nine patients (72% women) with mean age 56 ± 13 years were included. Annual exacerbation rate decreased from 4.7 (SD 3.7) to 1.3 (SD 2.5) (p < 0.001). The number of patients requiring OCS treatment decreased from 25 patients (36%, mean prednisone dose = 18 mg/day) to 13 patients (19%, mean prednisone dose = 9 mg/day) (p < 0.001). Twelve patients (48%) stopped OCS treatment. Forced expired volume in one second (FEV1) as percentage increased from 68% (SD 20) to 76% (SD 21) (p < 0.001). Fifty-six patients (81%) were considered responders to mepolizumab. No serious adverse events were detected during the study period.

CONCLUSIONS

Overall, this study demonstrates mepolizumab efficacy and safety in a cohort of patients with uncontrolled severe eosinophilic asthma in routine clinical practice.

Для цитирования: Enríquez-Rodríguez Ana Isabel, Hermida Valverde Tamara, Romero Álvarez Pedro, López-González Francisco Julián, Gullón Blanco Jose Antonio, Expósito Villegas Ana Rosa, Escobar Fernández María José, Beristáin Urquiza Ana María, Alonso Fernández Miguel Ángel, Gutiérrez Rodríguez Margarita, Castaño De Las Pozas Gema, Jiménez Pérez Jennifer, Fernández Mellado Roberto, García Clemente Marta María, Casan Clara Pere. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study.. The Journal of asthma : official journal of the Association for the Care of Asthma. 2021. DOI: 10.1080/02770903.2021.1897835.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.